Skip to main content
OpenTrials
Completed

NCT Number: NCT05137249

The Glycocalyx in COVID-19 Patients. A Pilot Study

The damage of the endothelial glycocalyx is based on microvascular endothelial dysfunction and typical for critical clinical conditions like sepsis, trauma, bleeding, shock, as well as ARDS. We aim to generate first hints regarding the impact of covid-19 disease on the (damage) of the endothelial glycocalyx. Furthermore, we want to investigate the potential coagulopathies, which go along with shedding of the glycocalyx. The detection of and the relation between the severity of the disease, as well as the extent of the glycocalyx damage during the observational period, as well as the hemostatic alterations, are aim of the study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COVID-19 Acute Lung Injury Cardiovascular Diseases Coagulation Disorder Coronaviridae Infections Coronavirus Infections Embolism and Thrombosis Endothelial Dysfunction Hematologic Diseases Hemic and Lymphatic Diseases Hemorrhagic Disorders Hemostatic Disorders Infections Lung Diseases Lung Injury Nidovirales Infections Pneumonia Pneumonia, Viral RNA Virus Infections Respiratory Tract Diseases Respiratory Tract Infections Thrombosis Vascular Diseases Virus Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Medical University of Vienna

Vienna, Austria

About this study

The damage of the endothelial glycocalyx is based on microvascular endothelial dysfunction and typical for critical clinical conditions like sepsis, trauma, bleeding, shock, as well as ARDS. We aim to generate first hints regarding the impact of covid-19 disease on the (damage) of the endothelial glycocalyx. Furthermore, we want to investigate the potential coagulopathies, which go along with shedding of the glycocalyx. The detection of and the relation between the severity of the disease, as well as the extent of the glycocalyx damage during the observational period, as well as the hemostatic alterations, are aim of the study.Circulating plasma syndecan-1 is measured as surrogat parameter for the extent of the glycocalyx damage.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • COVID-19 detected by PCR measures going along with clinical symptoms
  • age > 18 years

Exclusion criteria

  • refusal of study participation

Treatment and study plan

Primary outcomes

  1. extent of endothelial damage

    Time frame: up to 2 months

    circulating plasma syndecan-1 as surrogat parameter for endothelial damage is measures

Sponsors and collaborators

Lead sponsor

Medical University of Vienna

Other

Registry information

Acronym: Glycovid-19

Important dates

Study start
2020
Primary completion
2021
Study completion
2021
First posted
Nov 30, 2021
Registry last updated
Nov 30, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.